Study on sustainable and resilient supply of medical radioisotopes in the EU. Therapeutic Radionuclides
|Auteur||Joint Research Centre, Ligtvoet, Scholten, Davé, King, Petrosova, Chiti, Goulart De Medeiros, Joerger|
|Classificatie||6.07.4.60/51 (ALLERLEI - MEDISCHE ISOTOPEN - NUCLEAIRE GENEESKUNDE )|
Uit de publicatie:
Study on sustainable and resilient supply of medical radioisotopes in the EU Therapeutic Radionuclides 2021 Joint Research Centre Ligtvoet, A., Scholten, C., Davé, A., King, R., Petrosova, L., Chiti, A., Goulart De Medeiros, M., Joerger, A. Abstract This report presents an overview of the current use of radionuclides for medical therapy in Europe as well as an estimate on the amounts being used. It also provides the expert opinion of more than 200 professionals in the field of nuclear medicine and radiopharmacy on future growth potential of the use of therapeutic radionuclides. The research signals the paucity of information, and reiterates the call for joint European efforts for more reliable data. While historical practice in radionuclide therapy has not led to major supply concerns, the imminent approval of certain treatment options (for example PSMA linked to Lutetium-177 for prostate cancer) may lead to a rise in demand for Lutetium and other radionuclides that may pose challenges to European radionuclide producers. The shutdown of European research reactors without immediate replacement capacity, as well as a general ageing of the infrastructure is an unsolved issue that also requires concerted European action. While the market for therapeutic radionuclides is currently still small in comparison to the market for diagnostic radionuclides, the use of radiopharmaceuticals promises advances in the treatment of cancer. At the same time, technological developments for the production of these radionuclides are still uncertain and in early stages of market readiness. Supply is not fully secured, as the market is new and volatile. Future market developments are influenced by national reimbursement systems in reaction to radiopharmaceutical pricing, as well as complicated regulations that are determined by both radiation protection and pharmaceutical directives.